Peter de Keizer

Peter de Keizer has a strong background in cellular senescence and its implications in aging and cancer. Peter started their career as a PhD student studying FOXOs and their regulation under oxidative stress and oncogenic pathways. Peter then worked as a postdoctoral fellow, where they discovered the role of FOXO inhibition in triggering apoptosis in stressed and oncogenically mutated cells.

Peter also has experience as a visiting scientist at the Buck Institute, where they investigated how damaged cells can favor senescence over cell death. Peter identified the potential of targeting senescence in battling age-related diseases and cancer cells.

At Erasmus University Medical Center, Peter served as a group leader focused on senescence in cancer and aging. Their team developed a compound to selectively kill senescent cells and delay aging.

Peter founded Cleara Biotech, a company dedicated to developing compounds against specific subtypes of cellular senescence for clinical application against age-related diseases and therapy-resistant cancer.

Currently, Peter holds the position of Associate Professor at UMC Utrecht, specializing in senescence in cancer and aging. Their academic group focuses on understanding the molecular mechanisms behind cellular damage-induced senescence and the heterogeneity of senescence phenotypes.

Peter de Keizer began their education at Gymnasium Camphusianum, where they obtained their High School Diploma. After completing their high school education, they attended Utrecht University from 1999 to 2004, where they earned their Drs./MSc degree in Biomolecular Sciences. In 2003 and 2004, Peter de Keizer also studied at Harvard Medical School, obtaining an additional MSc degree in Biomolecular Science. However, the start and end years of this period of study were not provided.